RxDoctor Payments Data

Shelton Harrell

Critical Care Medicine · Nashville, TNNPI 1184920886

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by GSK at 54.3% of the total. Reporting peaked in 2021 at $6,816 and has fallen 94.2% since, to $393 in 2025. Among critical care medicine clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,307in general payments, 2019–2025

Across 43 payments — averaging $379.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$9K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Sanofi$2K
  • Bristol Myers Squibb$973
  • Karyopharm Therapeutics Inc.$720
  • Novartis$681
  • plus $786 from 8 others

What the payments were for

  • Consulting fees$3,14019%
  • Speaking & faculty fees$9,14356%
  • Travel & lodging$1,77611%
  • Food & beverage$2,23114%
  • Education$170%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,307 in reported general payments places this provider in the 90th percentile of 141 critical care medicine providers in Tennessee.

See all critical care medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$31,652
Medicare patients
203
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide80$1,390,333
PomalystPomalidomide34$814,864
Lenalidomide41$547,952
ImbruvicaIbrutinib14$223,061
ValacyclovirValacyclovir Hcl65$2,833
Fluconazole13$295
Levofloxacin14$245
Potassium Chloride14$222
Omeprazole19$146
Dexamethasone14$106
Gabapentin11$72
Atorvastatin Calcium13$49
Tamsulosin Hcl14$46
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$39
Montelukast Sodium14$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$973$1,390,33380 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$2,553$814,86434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 141 critical care medicine providers in Tennessee.

Other critical care medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →